Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS5855
• Study ID:
  31545
• Official title and acronym:
  Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  This study plans to identify and periodically update cohorts of patients with non-valvular atrial fibrillation at risk for stroke initating oral anticoagulants (dabigatran or warfarin) using electronic claims data from commercial insurance databases and to quantify associations between anticoagulant choice and the occurrence of selected outcomes.
• Study status:
  Finalised

Research institutions and networks

Institutions

Brigham and Women's Hospital

Study timelines

Date when funding contract was signed

Planned:06/01/2012

Actual:06/01/2012

Study start date

Planned:07/03/2014

Actual:07/03/2014

Data analysis start date

Planned:10/03/2014

Actual:10/03/2014

Date of interim report, if expected

Planned:30/04/2014

Date of final study report

Planned:31/03/2017

Actual:10/10/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable